Angiogenic tumor markers, antiangiogenic agents and radiation therapy

Expert Review of Anticancer Therapy

Volumn 3, Issue 3, 2003, Pages 357-366

  Chan, Linda W ^a   Camphausen, Kevin ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Angiogenesis; Antiangiogenic agents; Matrix metalloproteinase; Radiation; Tumor marker; Vascular endothelial growth factor

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; 4 DEDIMETHYLAMINOSANCYCLINE; AE 941; ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; ANGIOSTATIN; ANTINEOPLASTIC AGENT; BASIC FIBROBLAST GROWTH FACTOR; BEVACIZUMAB; ENDOSTATIN; EPIDERMAL GROWTH FACTOR; FUMAGILLOL CHLOROACETYLCARBAMATE; GEFITINIB; GELATINASE A; GELATINASE B; MARIMASTAT; MATRIX METALLOPROTEINASE; PLATELET DERIVED ENDOTHELIAL CELL GROWTH FACTOR; PRINOMASTAT; PROTEIN P53; REBIMASTAT; SEMAXANIB; TANOMASTAT; THALIDOMIDE; THROMBOSPONDIN; TRANSFORMING GROWTH FACTOR; TRASTUZUMAB; UNINDEXED DRUG; VASCULOTROPIN; VATALANIB;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ADVANCED CANCER; BREAST CANCER; CANCER RADIOTHERAPY; CANCER RESEARCH; CLINICAL TRIAL; COLORECTAL CANCER; DRUG MECHANISM; DRUG POTENTIATION; GASTROINTESTINAL TUMOR; GLIOBLASTOMA; HEAD AND NECK CANCER; HUMAN; KAPOSI SARCOMA; KIDNEY CANCER; LUNG NON SMALL CELL CANCER; LYMPHOMA; MOUSE; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; MYELOMA; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PROGNOSIS; PROSTATE CANCER; RADIOIMMUNOTHERAPY; REVIEW; TUMOR VASCULARIZATION; UROGENITAL TRACT CANCER; VON HIPPEL LINDAU DISEASE;

EID: 0038545713     PISSN: 14737140     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737140.3.3.357     Document Type: Review

References (97)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285, 1182-1186 (1971).
2. Fang J, Shing Y, Wiederschain D et al. Matrix metalloproteinase-2 is required for the switch to the angiogenic phenotype in a tumor model. Proc. Natl Acad. Sci. USA 97(5), 3884-3889 (2000).
3. Mayerhofer M, Valent P, Sperr WR, Griffin JD, Sillaber C. Bcr/abl induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1α, through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin. Blood 100(10), 3767-3775 (2002).
4. Dvorak HF, Nagy JA, Berse B et al. Vascular permeability factor, fibrin and the pathogenesis of the tumor stroma formation. Ann. NY Acad. Sci. 667, 110-111 (1992).
5. Rak J, Mitsuhashi Y, Bayko L et al. Mutant ras oncogenes upregulate VEGF/VPK expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res. 55, 4574-4580 (1995).
6. Kieser A, Weich HA, Brandner G, Marme D, Kolch W. Mutant p53 potentiates protein kinase c induction of vascular endothelial growth factor expression. Oncogene 9, 963-969 (1994).
7. McMahon G. VEGF receptor signaling in tumor angiogenesis. Oncologist 5 (Suppl. 1), 3-10 (2000).
8. Kaban K, Herbst RS. Angiogenesis as a target for cancer therapy. Hematol. Oncol. Clin. North Am. 16(5), 1125 (2002).
9. Poon RT, Fan ST, Wong J. Clinical implications of circulating angiogenic factors in cancer patients. J. Clin. Oncol. 19(4), 1207-1225 (2001).
10. Gorski DH, Beckett MA, Jaskowiak NT et al. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res. 59, 3374-3378 (1999).
11. Nakayama Y, Sako T, Shibao K et al. Prognostic value of plasma vascular endothelial growth factor in patients with colorectal cancer. Anticancer Res. 22(4), 2437-2442 (2002).
12. Hormbrey E, Gillespie P, Turner K et al. A critical review of vascular endothelial growth factor analysis in peripheral blood: is the current literature meaningful? Clin. Exp. Metastasis 19, 651-663 (2002).
13. Vihinen P, Kahari VM. Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets. Int. J. Cancer 99, 157-166 (2002).
14. Burke PA, DeNardo SJ. Anti-angiogenic agents and their promising potential in combined therapy. Crit. Rev. Oncol. Hematol. 39, 155-171 (2001).
15. Itoh T, Tanioka M, Matsuda H et al. Experimental metastasis is suppressed in MMP-9 deficient mice. Clin. Exp. Metastasis 17, 177-181 (1999).
16. Itoh T, Tanioka M, Yoshida H, Yoshioka T, Nishimoto H, Itohara S. Reduced angiogenesis and tumor progression in gelatinase α-deficient mice. Cancer Res. 58, 1048-1051 (1998).
17. Moses MA, Wiederschain D, Loughlin KR, Zurakowski D, Lamb CC, Freeman MR. Increased incidence of matrix metalloproteinases in urine of cancer patients. Cancer Res. 58(7), 1395-1399 (1998).
18. Linderholm B, Tavelin B, Grankvist K, Henriksson R. Vascular endothelial growth factor is of high prognostic value in nodenegative breast carcinoma. J. Clin. Oncol. 16, 3121-3128 (1998).
19. Smith BD, Stmith GL, Carter D, Sasaki CT, Haffty BG. Prognostic significance of vascular endothelial growth factor protein levels in oral and oropharyngeal squamous cell carcinoma. J. Clin. Oncol. 18, 2046-2052 (2000).
20. Kraft A, Weindel K, Ochs A et al. VEGF in the sera and effusions of patients with malignant and nonmalignant disease. Cancer 85, 178-187 (1999).
21. Verheul HM, Hoekman K, Jorna AS, Smit EF, Pinedo HM. Targeting vascular endothelial growth factor blockade: ascites and pleural effusion formation. Oncologist 5(Suppl. 1), 45-50 (2000).
22. Ondruschka C, Buhtz P, Motsch C et al. Prognostic value of MMP-2, -9 and TIMP-1, -2 immunoreactive protein at the invasive front in advanced head and neck squamous cell carcinomas. Pathol. Res. Pract. 198(8), 509-515 (2002).
23. Cai W, Song JD. Expression of matrix metalloproteinase and tissue inhibitors in ovarian tumors. Ai Zheng 21, 91-94 (2002).
24. Lengyel E, Schmalfeldt B, Konik E et al. Expression of latent matrix metalloproteinase-9 predicts survival in advanced ovarian cancer. Gynecol. Oncol. 82(2), 291-298 (2001).
25. Kuniyasu H, Ellis LM, Evans DB et al. Relative expression of E-cadherin and type IV collagenase genes predicts disease outcome in patients with resectable pancreatic carcinoma. Clin. Cancer Res. 5, 25-33 (1999).
26. Sienel W, Hellers J, Morresi-Hauf A et al. Prognostic impact of matrix metalloproteinase-9 in operable non-small cell lung cancer. Int. J. Cancer 103(5), 647-651 (2003).
27. Kuittinen O, Soini Y, Turpeenniemi-Hujanen T. Diverse role of MMP-2 and MMP-9 in the clinicopathological behavior of Hodgkin's lymphoma. Eur. J. Haematol. 69(4), 205-212 (2002).
28. Gerhards S, Jung K, Koenig F et al. Excretion of matrix metalloproteinases-2 and -9 in urine is associated with a high stage and grade of bladder carcinoma. Urology 57(4), 675-679 (2001).
29. Kausch I, Bohle A. Molecular aspects of bladder cancer III: prognostic markers of bladder cancer. Eur. Urol. 41, 15-29 (2002).
30. Gokaslan ZL, Chintala SK, York JE et al. Expression and role of matrix metalloproteinases MMP-2 and MMP-9 in human spinal column tumors. Clin. Exp. Metastasis 16, 721-728 (1998).
31. Kanoh Y, Akahoshi T, Ohara T et al. Expression of matrix metalloproteinase-2 and prostate-specific antigen in localized and metastatic prostate cancer. Anticancer Res. 22(3), 1813-1817 (2002).
32. Zeng ZS, Huang Y, Cohen AM, Guillem JG. Prediction of colorectal cancer relapse and survival via tissue RNA levels of matrix metalloproteinase-9. J. Clin. Oncol. 14, 3133-3140 (1996).
33. Gohji K, Fujimoto N, Hara I et al. Serum matrix metalloproteinase-2 and its density in men with prostate cancer as a new predictor of disease extension. Int. J. Cancer 79, 96-101 (1998).
34. Garbisa S, Scagliotti G, Masiero L et al. Correlation of serum matrix metalloproteinase levels with lung cancer metastasis and response to therapy. Cancer Res. 15, 4548-4549 (1992).
35. Li L, Zhang S, Lin H, Lin JY. Relationship of expression unbalance of matrix metalloproteinase and tissue inhibitor of metalloproteinase to invasiveness and metastasis in gastric carcinomas. Ai Zheng 21(3), 305-310 (2002).
36. Talvensaari-Mattila A, Paakko P, Blanco-Sequeiros G, Turpeenniemi-Hujanen T. MMP-2 positivity and age less than 40 years increases the risk for recurrence in premenopausal patients with node-positive breast carcinoma. Breast Cancer Res. Treat. 58, 287-293 (1999).
37. Chin KF, Greenman J, Gardiner E, Kumar H, Topping K, Monson J. Preoperative serum vascular endothelial growth factor can select patients for adjuvant treatment after curative resection in colorectal cancer. Br. J. Cancer 83, 1425-1431 (2000).
38. Poon RT, Ng IO, Lau C et al. Serum vascular endothelial growth factor predicts venous invasion in hepatocellular carcinoma. A prospective study. Ann. Surg. 233, 227-235 (2001).
39. Qian CN, Zhang CQ, Guo X et al. Elevation of serum vascular endothelial growth factor in male patients with metastatic nasopharyngeal carcinoma. Cancer 88, 2555-2561 (2000).
40. Jones A, Crew J. Vascular endothelial growth factor and its correlation with superficial bladder cancer recurrence rates and stage progression. Urol. Clin. North Am. 27, 191-197 (2000).
41. Meyer GE, Yu E, Siegal JA, Petteway JC, Blumenstein BA, Brawer MK. Serum basic fibroblast growth factor in men with and without prostate carcinoma. Cancer 76, 2304-2311 (1995).
42. Wolff JM, Fandel T, Borchers H, Brehmer B Jr, Jakse G. Transforming growth factor-β 1 serum concentration in patients with prostatic cancer and benign prostatic hypertrophy. Br. J. Urol. 81, 403-405 (1998).
43. Obermair A, Tempfer C, Hefler L et al. Concentration of vascular endothelial growth factor in the serum of patients with suspected ovarian cancer. Br. J. Cancer 77, 1870-1874 (1998).
44. Hazelton D, Nicosia RF, Nicosia SV. Vascular endothelial growth factor levels in ovarian cyst fluid correlate with malignancy. Clin. Cancer Res. 5, 823-829 (1999).
45. Choe G, Park JK, Jouben-Steele L et al. Active matrix metalloproteinase-9 expression is associated with primary glioblastoma subtype. Clin. Cancer Res. 8(9), 2894-2901 (2002).
46. Korem S, Kraiem Z, Shiloni E, Yehezkel O, Sadeh O, Resnick MB. Increased expression of matrix metalloproteinase-2: a diagnostic marker but not prognostic marker of papillary thyroid carcinoma. Isr. Med. Assoc. J. 4(4), 247-251 (2002).
47. Yamamoto S, Konishi I, Mandai M et al. Expression of vascular endothelial growth factor in epithelial ovarian neoplasms: correlation with clinicopathology and patient survival and analysis of serum VEGF levels. Br. J. Cancer 76, 1221-1227 (1997).
48. Yamamoto Y, Toi M, Kondo S et al. Concentrations of vascular endothelial growth factor in the sera of normal controls and cancer patients. Clin. Cancer Res. 2, 821-826 (1996).
49. Niedergethmann M, Hildenbrand R, Wostbrock B et al. High expression of vascular endothelial growth factor predicts early recurrence and poor prognosis after curative resection for ductal adenocarcinoma of the pancreas. Pancreas 25(2), 122-129 (2002).
50. Koshiba T, Hosotani R, Wada M et al. Involvement of matrix metalloproteinase-2 activity in invasion and metastasis of pancreatic carcinoma. Cancer 82(4) 642-650 (1998).
51. Hara I, Miyake H, Hara S, Arakawa S, Kamidono S. Significance of matrix metalloproteinases and tissue inhibitors of metalloproteinase expression in the recurrence of superficial transitional cell carcinoma of the bladder. J. Urol. 165, 1769-1772 (2001).
52. Cai M, Onoda K, Takao M et al. Degradation of tenascin-c and activity of matrix metalloproteinase-2 are associated with tumor recurrence in early stage nonsmall cell lung cancer. Clin. Cancer Res. 8(4), 1152-1156 (2002).
53. Niu Q, Tang Z, Ma Z, Qin L, Bao W, Zhang L. Relationship between serum matrix metalloproteinase-2 and metastasis and recurrence following radical hepatic resection in hepatocellular carcioma. Zhonghua Gan Zang Bing Za Zhi 9 (Suppl.), 58-60 (2001).
54. Yamamoto H, Itoh F, Adachi Y et al. Messenger RNA expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human hepatocellular cancer. Jpn. J. Clin. Oncol. 29, 58-62 (1999).
55. Salven P, Ruotsalainen T, Mattson K, Joensuu H. High pre-treatment serum level of vascular endothelial growth factor is associated with poor outcome in small-cell lung cancer. Int. J. Cancer 17, 144-146 (1998).
56. Hyodo I, Doi T, Endo H et al. Clinical significance of plasma vascular endothelial growth factor in gastrointestinal cancer. Eur. J. Cancer 34, 2041-2045 (1998).
57. Toi M, Bando H, Kuroi K. The predictive value of angiogenesis for adjuvant therapy in breast cancer. Breast Cancer 7(4), 311-314 (2000).
58. Inoue K, Kamada M, Slaton JW et al. The prognostic value of angiogenesis and metastasis-related genes for progression of transitional cell carcioma of the renal pelvis and ureter. Clin. Cancer Res. 8(6), 1863-1870 (2002).
59. Gupta VK, Jaskowiak NT, Beckett MA et al. Vascular endothelial growth factor enhances endothelial cell survival and tumor radioresistance. Cancer J. 8(1), 47-54 (2002).
60. Shintani S, Kiyota A, Mihara M et al. Association of preoperative radiation effect with tumor angiogenesis and vascular endothelial growth factor in oral squamous cell carcinoma. Jpn J. Cancer Res. 91 (10), 1051-1057 (2000).
61. Geng L, Donnelly E, McMahon G et al. Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy. Cancer Res. 61(6), 2413-2419 (2001).
62. Lee CG, Heijn M, di Tomaso E et al. Antivascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res. 60(19), 5565-5570 (2000).
63. Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J. Clin. Oncol. 20(21), 4368-4380 (2002).
64. Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nature Rev. Cancer 2(10), 727-739 (2002).
65. Rosen L. Antiangiogenic strategies and agents in clinical trials. Oncologist 5 (Suppl. 1), 20-27 (2000).
66. Harris AL. Von Hippel-Lindau syndrome: Target for antivascular endothelial growth factor receptor therapy. Oncologist 5 (Suppl. 1), 32-36 (2000).
67. Giles FJ, Cooper MA, Silverman L et al. Phase II study of SU5416-α small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor in patients with refractory myeloproliferative diseases. Cancer 97(8), 1920-1928 (2003).
68. Camphausen K, Menard C. Angiogenesis inhibitors and radiotherapy of primary tumors. Exp. Opin. Biol. Ther. 2(5), 477-481 (2002).
69. Dvorak H. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J. Clin. Oncol. 20(21), 4368-4380 (2002).
70. Carter SK. Clinical strategy for the development of angiogenesis inhibitors. Oncologist. 5(Suppl. 1), 51-54 (2000).
71. Teicher BA, Holden SA, Ara G et al. Antiangiogenic agents can increase tumor oxygenation and response to radiation therapy. Radiat. Oncol. Investig. 2, 269-276 (1995).
72. Jain RK. Normalizing tumor vasculature witih antiangiogenic therapy: a new paradigm for combination therapy. Nature Med. 7(9), 987-989 (2001).
73. Gasparini G, Weidner N, Maluta S et al. Intratumoral microvessel density and p53 protein: correlation with metastasis in head and neck squamous cell carcinoma. Int. J. Cancer 55, 739-744 (1993).
74. Koukourakis MI. Tumor angiogenesis and response to radiotherapy. Anticancer Res. 21(6B), 4285-4300 (2001).
75. Takano S, Tsuboi K, Matsumura A, Nose T. Antivascular endothelial growth factor antibody and nimustine as combined therapy: effects on tumor growth and angiogenesis in human glioblastoma xenografts. Neuro-oncol. 5(1), 1-7 (2003).
76. Mauceri HJ, Hanna NN, Beckett MA et al. Combined effects of angiostatin and ionizing radiation in antitumor therapy. Nature 395(6690), 287-291 (1998).
77. Hanna NN, Seetharam S, Mauceri HJ et al. Antitumor interaction of short-course endostatin and ionizing radiation. Cancer J. 6(5), 287-293 (2000).
78. Camphausen K, Moses MA, Beecken WD, Khan MK, Folkman J, O'Reilly MS. Radiation therapy to a primary tumor accelerates metastatic growth in mice. Cancer Res. 61(5), 2207-2211 (2001).
79. Hess C, Vuong V, Hegyi I et al. Effect of VEGF receptor inhibitor ptk787/zk222584 combined with ionizing radiation on endothelial cells and tumor growth. Br. J. Cancer 85(12), 2010-2016 (2001).
80. Lund EL, Bastholm L, Kristjansen PE. Therapeutic synergy of TNP-470 and ionizing radiation effects on tumor growth, vessel morphology and angiogenesis in human glioblastoma multiforme xenografts. Clin. Cancer Res. 6, 971-978 (2000).
81. Ning S, Laird D, Cherrington JM, Knox SJ. The anti-angiogenic agents SU5416 and SU6668 increase the antitumor effects of fractionated irradiation. Radiat. Res. 157(1), 45-51 (2002).
82. Griffin RJ, Williams BW, Wild R, Cherrington JM, Park H, Song CW. Simultaneous inhibition of the receptor kinase activity of vascular endothelial, fibroblast and platelet-derived growth factors suppresses tumor growth and enhances tumor radiation response. Cancer Res. 62(6), 1702-1706 (2002).
83. Cha S, Johnson G, Wadghiri YZ et al. Dynamic, contrast-enhanced perfusion MRI in mouse gliomas: correlation with histopathology. Magn. Reson. Med. 49(5), 848-855 (2003).
84. Daldrup-Link HE, Brasch RC. Macromolecular contrast agents for MR mammography: current status. Eur. Radiol. 13(2), 354-365 (2003).
85. Carriero A, Ambrossini R, Mattei PA, Angelucci D, Bonomo L. Magnetic resonance of the breast: correlation between enhancement patterns and microvessel density in malignant tumors. J. Exp. Clin. Cancer Res. 21(3 Suppl.), 83-87 (2002).
86. Marzola P, Farace P, Calderan L et al. In vivo mapping of fractional plasma volume (fpv) and endothelial transfer coefficient (kps) in solid tumors using a macromolecular contrast agent: correlation with histology and ultrastructure. Int. J. Cancer 104(4), 462-468 (2003).
87. Padhani AR. Dynamic contrast-enhanced MRI in clinical oncology: current status and future directions. J. Magn. Reson. Imaging 16(4), 407-422 (2002).
88. Gulec SA, Gaffga CM, Anthony CT, Su LJ, O'Leary JP, Woltering EA. Anti-angiogenic therapy with somatostatin receptor-mediated in situ radiation. Am. Surg. 67(11), 1068-1071 (2001).
89. Shi W, Teschendorf C, Muzyczka N, Siemann DW. Gene therapy delivery of endostatin enhances the treatment efficacy of radiation. Radiother. Oncol. 66(1), 1-9 (2003).
90. Perletti G, Concari P, Giardini R et al. Antitumor activity of endostatin against carcinogen-induced rat primary mammary tumors. Cancer Res. 60, 1793-1796 (2000).
91. Landuyt W, Ahmed B, Nuyts S et al. In vivo antitumor effect of vascular targeting combined with either ionizing radiation or anti-angiogenesis treatment. Int. J. Radiat. Oncol. Biol. Phys. 49(2), 443-450 (2001).
92. Murata R, Nishimura Y, Hiraoka M. An anti-angiogenic agent (TNP-470) inhibited reoxygenation during fractionated radiotherapy of murine mammary carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 37(5), 1107-1113 (1997).
93. Greenberger JS. Antitumor interaction of short course endostatin and ionizing radiation. Cancer J. 6(5), 279-281 (2000).
94. Minchinton AI, Fryer KH, Wendt KR, Clow KA, Hayes MM. The effect of thalidomide on experimental tumors and metastases. Anticancer Drugs 7(3), 339-343 (1996).
95. Gorski DH, Mauceri HJ, Salloum RM, Halpern A, Seetharam S, Weichselbaum RR. Prolonged treatment with angiostatin reduces metastatic burden during radiation therapy. Cancer Res. 63, 308-311 (2003).
96. Gorski DH, Mauceri HJ, Salloum RM et al. Potentiation of the antitumor effect of ionizing radiation by brief concomitant exposures to angiostatin. Cancer Res. 58(24), 5686-5689 (1998).
97. Hari D, Beckett MA, Sukhatme VP et al. Angiostatin induces mitotic cell death of proliferating endothelial cells. Mol. Cell Biol. Res. Commun. 3(5), 277-282 (2000).